| Document |
Document Title |
|
WO/2023/280136A1 |
The present invention relates to a trideuteromethyl-substituted pyrazino pyrazino quinolinone derivative, and a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a trideuteriometh...
|
|
WO/2023/283213A1 |
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or dis...
|
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/281046A1 |
The present invention provides novel bispidone ligands and transition metal complexes thereof, especially iron and manganese complexes thereof. Furthermore, the present invention also relates to the use of said bispidone ligands and comp...
|
|
WO/2023/283369A1 |
Provided herein are small molecule protein kinase modulators, pharmaceutical compositions comprising such, and their uses in treating one or more conditions.
|
|
WO/2023/275230A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2023/275744A1 |
The present disclosure relates to 3-substituted-5-(1-(quinolin-2-yl)piperidin-4-yl)-1,2,4-oxad
iazole derivatives for use in the treatment and/or prevention of tuberculosis. Formula (I)
|
|
WO/2023/275337A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/274397A1 |
Disclosed are a cyclin-dependent kinase 2 (CDK2) inhibitor as shown in formula I, a preparation method therefor and use thereof. The compound of formula I can be used as a CDK inhibitor for preventing and/or treating diseases associated ...
|
|
WO/2023/274251A1 |
The present invention relates to a polycyclic compound for inhibiting RNA helicase DHX33, and an application of the compound. In particular, the present invention relates to a compound as represented by formula I or a pharmaceutically ac...
|
|
WO/2023/274280A1 |
A crystal form of a compound of general formula (I), a preparation method therefor, a pharmaceutical composition containing the therapeutically effective amount of the crystal form, and the use thereof as a PD-1/PD-L1 inhibitor in the tr...
|
|
WO/2023/277331A1 |
The present invention relates to: a pyrrolo[3,2-c]pyridine derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same as an active ingredient, wherein the pharmaceutical composition is used...
|
|
WO/2023/274204A1 |
The present application provides a nitrogenous polycyclic aromatic compound and a preparation method therefor and an application thereof. The nitrogenous polycyclic aromatic compound in the present application is a compound represented b...
|
|
WO/2023/275366A1 |
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 ...
|
|
WO/2023/278686A1 |
Compounds having activity as inhibitors of MNK are provided, including compounds of Formula (I): or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein R1a, R1b, R1, R2, R3, R4d, R4c, Z1, and n are as ...
|
|
WO/2023/278325A1 |
Disclosed are bifunctional compounds (degraders) that target ALK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the bifunctional compounds to treat diseases and disorders cha...
|
|
WO/2023/275705A1 |
The present invention provides a process for the preparation of bicyclic anthranilic diamides of formula (I) or of salts thereof, wherein, R1, R2, Ra, Rb and R3 are as described in the description. More particularly, the present inventio...
|
|
WO/2023/275333A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/274390A1 |
Disclosed are a Bruton's tyrosine kinase and a mutant degrader thereof, or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug f...
|
|
WO/2023/275336A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/278564A1 |
The present invention relates to compounds that inhibit Protein Arginine N- Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods...
|
|
WO/2023/274203A1 |
A nitrogen-containing polycyclic aromatic compound, a preparation method therefor, and an application thereof. The nitrogen-containing polycyclic aromatic compound has a structure of formula I; the compound has excellent broad-spectrum a...
|
|
WO/2023/275542A1 |
This invention relates to compounds comprising a pyrrolopyridone core, and pharmaceutically-acceptable salts and compositions of such compounds. The compounds herein are useful as anti-inflammatory and/or other therapies.
|
|
WO/2023/274242A1 |
Provided are a crystal form of a phenyl[a]indole[2,3-g]quinolizine compound, salts thereof and crystal forms of salts, and a preparation method therefor and an application thereof. The structure of the phenyl[a]indole[2,3-g]quinolizine c...
|
|
WO/2023/277313A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2023/278729A1 |
The present application provides radioisotope-containing compounds that are, e.g., mGluR2 modulators. Methods of imaging brain of a patient, as well as methods of diagnosing and monitoring treatment of psychiatric or neurological disorde...
|
|
WO/2022/270980A1 |
The present invention relates to a novel compound as a protein kinase inhibitor, particularly, a RON inhibitor.
|
|
WO/2022/268088A1 |
The present invention relates to a tricyclic compound used as a GPR84 antagonist, and in particular relates to a tricyclic compound having a structure shown in formula I, and tautomers, stereoisomers, hydrates, solvates, pharmaceutically...
|
|
WO/2022/268066A1 |
The present invention relates to a protein degradation agent, and a preparation method therefor and a use thereof. The protein degradation agent can degrade various proteins comprising c-Myc protein, and can therefore be used for the pre...
|
|
WO/2022/271727A1 |
Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), a...
|
|
WO/2022/270881A1 |
The present invention relates to a novel compound as a protein kinase inhibitor.
|
|
WO/2022/271612A1 |
The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/270979A1 |
The present invention relates to a novel compound as a protein kinase inhibitor, especially as a RON inhibitor.
|
|
WO/2022/271562A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
|
|
WO/2022/269531A1 |
This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention fur...
|
|
WO/2022/271677A1 |
The application relates to diacylglycerol kinase modulating quinazolin-2-one derivatives of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV ...
|
|
WO/2022/271630A1 |
The present disclosure provides a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/271823A1 |
The disclosure includes compounds of Formula (1)-(4) wherein each of Warhead, R1, R2, R3, L1, L2, L3, L4, L5, L6, R, Q1, Q2, Q3, W1, W2, m, n, and i, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoi...
|
|
WO/2022/269049A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, A, L1, L2, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formu...
|
|
WO/2022/271659A1 |
The application relates to diacylglycerol kinase modulating compounds of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B viru...
|
|
WO/2022/269008A1 |
The present invention relates to a crystalline form of sotorasib and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of sotorasib of the present inventi...
|
|
WO/2022/268026A1 |
The present invention relates to 1,2,4-triazole compounds as AXL inhibitors. These compounds are suitable for treating or preventing AXL receptor tyrosine kinase-induced diseases.
|
|
WO/2022/268063A1 |
The present invention relates to the field of chemical pharmacy, relates to a crystal form of a pyrimidine derivative and a preparation method therefor, and specifically relates to crystal forms A, B, C, D, and E of a compound of formula...
|
|
WO/2022/271650A1 |
The application relates to diacylglycerol kinase modulating compounds of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B viru...
|
|
WO/2022/268179A1 |
Provided herein are compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II),...
|
|
WO/2022/271749A1 |
The present disclosure provides a compound represented by structural formula (I):or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/271613A1 |
The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/268849A1 |
A novel crystalline formof 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine hemisuccinate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel...
|
|
WO/2022/268209A1 |
Disclosed are a derivative having a pyrimidine-fused cyclic structure, and the use thereof. The compound has a significant inhibitory effect on SOS1 protein activity; can be used as an SOS1 protein inhibitor; has excellent druggability; ...
|
